Noninvasive blood miRNA test to screen for multiple gastrointestinal cancers.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This retrospective international, multi-center analysis will use archived peripheral blood samples from adults with major gastrointestinal cancers (including HCC, CCA, PDAC, ESCC, GC, and CRC) and non-malignant controls. Small RNA sequencing will generate circulating miRNA expression profiles followed by preprocessing, normalization, and batch-effect correction to harmonize data across cohorts and platforms. Machine-learning feature selection and classifier development (for example LASSO, mRMR, SVM, Random Forest, XGBoost) will be used to derive a compact miRNA panel that distinguishes cancer from non-cancer and to explore tumor-origin signals. The resulting signature will undergo multi-center training and validation to test robustness across geographic regions, sequencing platforms, and clinical demographics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults aged 18 years or older at the time of blood sample collection.
2. Patients with a confirmed diagnosis of one of the following gastrointestinal cancers: Hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), Pancreatic ductal adenocarcinoma (PDAC), Esophageal squamous cell carcinoma (ESCC), Gastric cancer (GC), Colorectal cancer (CRC), Non-cancer control participants, including healthy volunteers or patients with benign gastrointestinal conditions.
3. Availability of retrospective blood samples collected according to institutional protocols.
4. Willingness to allow use of de-identified clinical and demographic data for research purposes.

Exclusion Criteria:

* other active malignancies; insufficient sample quality/volume; recent chemotherapy/radiotherapy/surgery; any condition preventing reliable participation.

Where it's running

• City of Hope Nat Medical Ctr
  Duarte, California, United States Recruiting

Study contacts

• Principal investigator: Ajay Goel, PhD — City of Hope Medical Center
• Study coordinator: Junyong Weng, PhD
• Email: juweng@coh.org
• Phone: 06263151444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• Personalized mRNA tumor vaccine plus standard therapy for high-risk recurrent solid tumors

  This early-phase study tests XH001, a personalized mRNA neoantigen vaccine, with standard adjuvant treatment in people with high-risk recurrent solid cancers after surgery to see if it’s safe and may help delay relapse.

  Recruiting at 2 sites Phase 1 Shenzhen Xinhe Biomedical · Beijing and 1 other locations · NCT07594964

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.